Table 4.

Diagnostic value of early microRNA biomarkers for HCC.

	HCC Patients (number)	Comparison/Control Subjects (number)	Plasma	Sensitivity (%)	Specificity (%)	AUC	Reference
miR-139	31	31 HBV hepatitis	Serum	58.61	80.6	0.76	[52]
miR-139	38	42 HCV hepatitis and 45 HCV liver cirrhosis	Serum	85.71	64.29	0.863	[53]
miR-182	103	47 chronic hepatitis 39 liver cirrhosis 9 non-alcoholic fatty liver disease (NAFLD)	Serum	78.6	91.58	0.911	[58]
miR-182	40	20 HCV non-cirrhotic hepatitis	Serum	72.5	65	0.675	[55]
miR-150	40	40 healthy controls	Serum	60	70	0.674	[52]
miR-331-3p	103	47 chronic hepatitis 39 liver cirrhosis 9 NAFLD	Serum	79.61	86.32	0.89	[58]
miR-199a-3p	78	156 healthy controls	Serum	71.8	86.1	0.883	[57]
miR-375	78	156 healthy controls	Serum	52.3	72.7	0.637	[54]